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Abstract: OBJECTIVES: Randomized clinical trials that enroll patients in critical or emergency care
(acute care) setting are challenging because of narrow time windows for recruitment and the inability of
many patients to provide informed consent. To assess the extent that recruitment challenges lead to ran-
domized clinical trial discontinuation, we compared the discontinuation of acute care and nonacute care
randomized clinical trials. DESIGN: Retrospective cohort of 894 randomized clinical trials approved by
six institutional review boards in Switzerland, Germany, and Canada between 2000 and 2003. SETTING:
Randomized clinical trials involving patients in an acute or nonacute care setting. SUBJECTS AND IN-
TERVENTIONS: We recorded trial characteristics, self-reported trial discontinuation, and self-reported
reasons for discontinuation from protocols, corresponding publications, institutional review board files,
and a survey of investigators. MEASUREMENTS AND MAIN RESULTS: Of 894 randomized clinical
trials, 64 (7%) were acute care randomized clinical trials (29 critical care and 35 emergency care). Com-
pared with the 830 nonacute care randomized clinical trials, acute care randomized clinical trials were
more frequently discontinued (28 of 64, 44% vs 221 of 830, 27%; p = 0.004). Slow recruitment was
the most frequent reason for discontinuation, both in acute care (13 of 64, 20%) and in nonacute care
randomized clinical trials (7 of 64, 11%). Logistic regression analyses suggested the acute care setting
as an independent risk factor for randomized clinical trial discontinuation specifically as a result of slow
recruitment (odds ratio, 4.00; 95% CI, 1.72-9.31) after adjusting for other established risk factors, in-
cluding nonindustry sponsorship and small sample size. CONCLUSIONS: Acute care randomized clinical
trials are more vulnerable to premature discontinuation than nonacute care randomized clinical trials and
have an approximately four-fold higher risk of discontinuation due to slow recruitment. These results
highlight the need for strategies to reliably prevent and resolve slow patient recruitment in randomized
clinical trials conducted in the critical and emergency care setting.
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Objectives: Randomized clinical trials that enroll patients in critical 
or emergency care (acute care) setting are challenging because 
of narrow time windows for recruitment and the inability of many 
patients to provide informed consent. To assess the extent that 
recruitment challenges lead to randomized clinical trial discontinu-
ation, we compared the discontinuation of acute care and non-
acute care randomized clinical trials.
Design: Retrospective cohort of 894 randomized clinical trials 
approved by six institutional review boards in Switzerland, Germany, 
and Canada between 2000 and 2003.
Setting: Randomized clinical trials involving patients in an acute or 
nonacute care setting.
Subjects and Interventions: We recorded trial characteristics, 
self-reported trial discontinuation, and self-reported reasons 
for discontinuation from protocols, corresponding publications, 
institutional review board files, and a survey of investigators.
Measurements and Main Results: Of 894 randomized clinical trials, 
64 (7%) were acute care randomized clinical trials (29 critical care 
and 35 emergency care). Compared with the 830 nonacute care 
randomized clinical trials, acute care randomized clinical trials were 
more frequently discontinued (28 of 64, 44% vs 221 of 830, 27%; 
p = 0.004). Slow recruitment was the most frequent reason for 
discontinuation, both in acute care (13 of 64, 20%) and in non-
acute care randomized clinical trials (7 of 64, 11%). Logistic 
regression analyses suggested the acute care setting as an inde-
pendent risk factor for randomized clinical trial discontinuation 
specifically as a result of slow recruitment (odds ratio, 4.00; 95% 
CI, 1.72–9.31) after adjusting for other established risk factors, 
including nonindustry sponsorship and small sample size.
Conclusions: Acute care randomized clinical trials are more vul-
nerable to premature discontinuation than nonacute care ran-
domized clinical trials and have an approximately four-fold higher 
risk of discontinuation due to slow recruitment. These results 
highlight the need for strategies to reliably prevent and resolve 
slow patient recruitment in randomized clinical trials conducted 
in the critical and emergency care setting. (Crit Care Med 2015; 
XX:00–00)
Key Words: critical care; early termination of clinical trials; emergency 
medicine; ethics committees; randomized controlled trials
Randomized clinical trials (RCTs) enrolling patients who are acutely ill in the critical care or emergency care (acute care) setting are particularly challenging. 
One difficulty concerns the informed consent that is typically 
sought from substitute decision makers who are not always 
available or are difficult to identify (1). When substitute deci-
sion makers are available, they are often overwhelmed and 
under stress because of the need to decide rapidly on poten-
tially life-saving interventions (1). Narrow time windows also 
challenge the recruiting staff who must quickly identify eligible 
patients and initiate study procedures (2). Another barrier to 
efficient recruitment can be the prohibition of coenrollment of 
patients into more than one RCT by protocols, physicians, or 
institutional review boards (IRBs) (1). Finally, decision making 
in multidisciplinary settings such as critical or emergency care 
is typically a shared process and thus more individuals might 
decline to proceed or continue with the research.
A prospective study of critically ill adults in 23 Canadian 
ICUs found that 57% of opportunities to recruit eligible 
patients into studies (mostly RCTs) are either missed or infea-
sible (1). In two U.S. studies, the proportion of missed oppor-
tunities was 69% (94 of 136) in an ICU (3) and 47% (563 of 
1,202) in a trauma center (4). Others have described lessons 
learned from acute care RCTs that were discontinued due to 
slow recruitment (5–10). Lack of substitute decision makers 
was the most common reason for slow recruitment in a trial 
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of acute lung injury (5), and inability to complete the recruit-
ment interview was the most common reason for slow recruit-
ment in a trial enrolling patients with palliative care needs in 
an emergency department (9). However, the frequency with 
which recruitment challenges actually lead to premature dis-
continuation of acute care RCTs in comparison to nonacute 
care RCTs is unknown.
The objective of this study was to compare the risk for trial 
discontinuation, in particular due to slow recruitment, in a large 
sample of acute and nonacute care RCTs approved by IRBs.
METHODS
Study Design and Sample
We conducted a retrospective cohort study using RCTs 
approved between 2000 and 2003 by six IRBs in Switzerland 
(Basel, Lucerne, Zurich, and Lausanne), Germany (Freiburg), 
and Canada (Hamilton). The IRBs were responsible for human 
research in large university centers and additional hospitals 
in their respective catchment areas. We approached the IRBs 
through existing contacts in order to acquire our convenience 
sample. To minimize the number of ongoing or unpublished 
RCTs, we focused on protocols that had been approved more 
than 10 years ago. For this analysis, we excluded protocols of 
RCTs that involved only healthy volunteers, RCTs that were 
never started, and RCTs that investigators reported as ongoing 
in our survey as of April 2013 (see below). The participating 
IRBs approved this study or explicitly stated that no formal 
ethical approval was necessary. A detailed study protocol (11), 
an analysis of the dataset describing the prevalence of discon-
tinued trials across medical specialties (12), and two ancillary 
analyses of the dataset (13, 14) are published elsewhere.
Definitions
Two researchers independently classified RCTs as acute care if 
they enrolled 1) patients receiving critical care irrespective of 
when acute symptoms occurred (critical care) or 2) emergency 
patients who received the study intervention within 24 hours 
of presentation with acute symptoms (emergency care). Dis-
agreements were resolved by discussion or consultation with 
a clinician who was familiar with the RCT topic. We did not 
consider an RCT as acute care if patients consented to surgical 
intensive care before they received elective surgery—that is, if 
the recruitment took place in a nonacute situation.
We considered an RCT discontinued if the investigators indi-
cated trial discontinuation in correspondence with IRBs, in jour-
nal publications, or in their response to our survey (see below). 
If still unclear, we additionally classified trials as discontinued 
if the actual sample size was less than a prespecified thresh-
old of 90% of the target sample size (for studies with known 
achieved and target sample size). Accordingly, we considered an 
RCT completed if at least 90% of the targeted sample size was 
recruited and the investigators did not indicate discontinuation. 
We recorded all reasons for trial discontinuation. If we could not 
elucidate the reason for RCT discontinuation, we classified the 
trial as discontinued due to unknown causes (11, 12).
Data Sources and Extraction
Reviewers trained in trial methodology abstracted 30% of 
RCT protocols independently and in duplicate using pretested 
forms with detailed written instructions and following formal 
calibration exercises with all data abstractors. Disagreements 
arising in duplicate review were resolved by discussion. Single 
investigators abstracted the remaining RCT protocols, with 
periodic duplicate agreement checks from a random sample of 
protocols at several points during the process.
We followed-up on the completion status and publication 
history of RCTs as of April 27, 2013 by using information 
from IRB files and by conducting comprehensive searches for 
corresponding publications in electronic databases and trial 
registries. If trial completion or publication status remained 
unclear, we surveyed the investigator by sending them a stan-
dardized questionnaire through the overseeing IRB. All cor-
responding publications were abstracted independently and 
in duplicate; disagreements were resolved by consensus or by 
third-party adjudication.
Statistical Analyses
We present trial discontinuation, reported reasons, and pub-
lication status as frequencies and percentages, stratified by 
acute care and nonacute care RCTs. We explored differences 
between acute and nonacute care RCTs by using chi-square or 
Fisher exact tests for proportions, t tests for normally distrib-
uted, and rank sum tests for non-normally distributed con-
tinuous variables. We considered two-tailed p value less than 
or equal to 0.05 statistically significant and did not correct for 
multiple testing.
We investigated possible factors associated with RCT dis-
continuation due to slow recruitment by using multivariable 
logistic regression. As prespecified (11, 12), we limited our 
regression analysis to completed RCTs and RCTs discontin-
ued due to slow recruitment and excluded RCTs with other 
reasons for discontinuation. Assuming different recruitment 
and discontinuation patterns, we additionally excluded RCTs 
that were explicitly labeled as pilot RCTs (5 acute care and 46 
nonacute care) and RCTs that randomized clusters such as 
hospitals or families (0 acute care and 8 nonacute care RCTs) 
from our regression model. We investigate the incremental risk 
associated with acute care (vs nonacute care) after adjustment 
for previously examined prespecified protocol-level variables 
(11, 12): investigator sponsorship (vs industry), planned sam-
ple size (in decrements of 100), center status (multicenter vs 
single center), crossover design (vs parallel), type of control 
intervention (active control vs placebo or nonactive interven-
tion), any reported method to predict recruitment rate (vs 
no method reported), and methodologic or logistic support 
from a contract research organization or clinical trial unit (vs 
no support reported). In addition, we adjusted for pediatric 
RCTs (vs adult), another setting-specific potential risk factor 
for slow recruitment (11). The event-to-variable ratio was 10 
(90 discontinuations due to slow recruitment and 9 explana-
tory variables). We conducted a complete case analysis and 
sensitivity analyses by using multiple imputations for missing 
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information about trial discontinuation (missing in 5 acute 
and 66 nonacute care RCTs), reasons for discontinuation 
(missing in 1 acute and 24 nonacute care RCTs), and sample 
size (missing in 1 acute and 11 nonacute care RCTs) (15).
RESULTS
RCT Characteristics
We included 894 RCTs in the analysis (Fig. 1). Of those, 64 (7%) 
recruited patients in an acute care setting and 830 recruited patients 
in a nonacute care setting. The 64 acute care RCTs included 29 
critical care RCTs (17 adult and 12 pediatric) and 35 emergency 
care RCTs (14 stroke trials, 13 acute coronary syndrome trials, and 
8 others). Nonacute RCTs included four postsurgical critical care 
trials for which patients consented preoperatively and three RCTs 
that recruited emergency care patients but started the interven-
tion not within 24 hours (all 48 hr or later).
Most characteristics of critical and emergency care RCTs 
were similar (Table 1). Critical care RCTs had on average a 
shorter follow-up (median 0.9 vs 3.0 mo; p = 0.032), were less 
frequently labeled as pilot trial (0% vs 17%; p = 0.028), were 
less frequently sponsored by industry (41% vs 71%; p = 0.030), 
and more frequently enrolled children (41% vs 3%; p < 0.001) 
than emergency care RCTs.
Acute care RCTs as compared with nonacute care RCTs 
had a slightly larger planned sample size (median 300 vs 260; 
p = 0.023), a shorter planned follow-up (median 2.8 vs 6 mo; 
p < 0.001), were more frequently overseen by a data safety and 
monitoring board (DSMB) (56% vs 27%; p < 0.001), more fre-
quently had planned interim analyses (47% vs 31%; p = 0.015), 
more frequently included a placebo or no-treatment arm (78% 
vs 58%; p = 0.003), more frequently enrolled children (20% vs 
9%; p = 0.005), and less frequently reported quality of life as 
predefined outcome (11% vs 38%; p < 0.001). The remaining 
characteristics did not differ significantly between acute and 
nonacute care RCTs (Table 1).
Of the 64 acute care RCTs, 37 (58%) were published as a 
peer-reviewed journal article, 6 (9%) in abstract format only, 
and 21 (33%) were not published at a median follow-up of 
11.6 years from IRB approval. The respective publication rates 
in the 830 nonacute care RCTs were similar: 493 (59%) peer-
reviewed journal articles, 50 (6%) abstracts, and 286 (35%) 
not published (difference not formally tested, see Discussion 
section). The year of publication ranged from 2001 to 2013, 
with a median in 2006. Confidentiality agreements with col-
laborating IRBs do not allow us to provide a list of references 
of all included RCT publications.
Discontinuation
Of the 894 RCTs, 575 (64%) were completed and 249 (28%) 
were discontinued prior to enrolling the target sample, and 
the completion status remained unclear in 71 RCTs (8%) 
(Table 2). We determined RCT discontinuation from the pub-
lication alone (61 of 249, 25%), the survey alone (69 of 249, 
28%; response rate 80%), IRB file alone (67 of 249, 27%), com-
bined sources (27 of 249, 11%), or because the actual sample 
size was less than 90% of the target sample size (25 of 249, 
10%, including one acute care trial).
Acute care RCTs were more frequently discontinued 
(28 of 64, 44%) than nonacute care RCTs (221 of 830, 27%; 
p = 0.004). Unknown com-
pletion status was balanced 
between settings. Slow recruit-
ment was the most frequent 
reason for discontinuation, 
both in acute care (13 of 64, 
20%) and nonacute care RCTs 
(87 of 830, 11%) (Table 2). 
Multivariable logistic regres-
sion identified acute care RCTs 
as an independent incremental 
risk factor for discontinua-
tion due to slow recruitment 
(adjusted odds ratio [OR], 
4.00; 95% CI, 1.72–9.31). 
Investigator sponsorship (OR, 
4.45; 95% CI, 2.59–7.65) and 
small planned sample size 
(OR, 1.05; 95% CI, 1.01–1.09, 
in decrements of 100) were 
also significantly associated 
with discontinuation due to 
slow recruitment (Table 3). 
Multiple imputations for miss-
ing information regarding trial 
discontinuation and sample 
Figure 1. Trial flow diagram illustrating sample generation. IRB = institutional review board, RCT = randomized 
clinical trial.
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TAbLE 1. Characteristics of Acute Care and Nonacute Care Randomized Clinical Trials
RCT Characteristics
Critical Care  
(n = 29)
Emergency Care  
(n = 35)
Total Acute Care  
(n = 64)
Total Nonacute Care  
(n = 830)
Planned target sample size, median (IQR) 235 (175–680) 400 (153–2,080) 300 (158–1,200) 260 (100–600)
Planned centers (%)
  Multiple 23 (79) 30 (86) 53 (83) 688 (83)
  Single 6 (21) 5 (14) 11 (17) 138 (17)
  Unclear 0 0 0 4 (0.5)
Unit of randomization (%)
  Individuals 29 (100) 35 (100) 64 (100) 815 (98)
  Clusters 0 0 0 12 (1)
  Body parts 0 0 0 3 (0.4)
Pediatric trial (%) 12 (41) 1 (3) 13 (20) 73 (9)
Study design (%)
  Parallel 26 (90) 34 (97) 60 (94) 776 (94)
  Crossover 2 (7) 0 2 (3) 39 (5)
  Factorial 1 (3) 1 (3) 2 (3) 13 (2)
  Unclear 0 0 0 2 (0.2)
Study purpose (%)
  Superiority 25 (86) 30 (86) 55 (86) 597 (72)
  Noninferiority 3 (10) 3 (7) 6 (9) 133 (16)
  Unclear 1 (3) 2 (6) 3 (5) 100 (12)
Research ethics committee (%)
  Basel 3 (10) 11 (31) 14 (22) 207 (25)
  Hamilton 9 (31) 10 (29) 19 (30) 159 (19)
  Freiburg 6 (21) 7 (20) 13 (20) 259 (31)
  Lausanne 6 (21) 5 (14) 11 (17) 138 (17)
  Zürich 5 (17) 1 (3) 6 (9) 37 (5)
  Lucerne 0 1 (3) 1 (2) 30 (4)
  Labeled as pilot RCT 0 6 (17) 6 (9) 63 (8)
  Industry sponsorship 12 (41) 25 (71) 37 (58) 514 (62)
Comparison group(s) (%)
  Included placebo or no treatment (often add-on RCTs) 24 (83) 26 (74) 50 (78) 483 (58)
  Active comparator(s) only 5 (17) 9 (26) 14 (22) 347 (42)
Data safety and monitoring board mentioned (%) 12 (41) 24 (69) 36 (56) 221 (27)
Stopping rule mentioned (%) 5 (17) 9 (26) 14 (22) 141 (17)
Interim analysis mentioned (%) 14 (48) 16 (46) 30 (47) 259 (31)
Follow-up, months from randomization, median (IQR) 0.9 (0.9–5.9) 3.0 (1.0–12.0) 2.8 (0.9–6.0) 6.0 (2.5–13.0)
Method to predict recruitment rate mentioned (%) 7 (24) 2 (6) 9 (14) 72 (9%)
Pilot study including informed consent (%) 3 (10) 0 3 (5) 8 (1)
Reported methodologic/logistic support (%) 11 (38) 18 (51) 29 (45) 357 (43)
Primary outcome specified (%) 24 (83) 31 (89) 55 (86) 778 (94)
Quality of life outcome planned (%) 3 (10) 4 (11) 7 (11) 312 (38)
RCT = randomized clinical trial, IQR = interquartile range.
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size did not alter the results (Supplemental Digital Content 1, 
http://links.lww.com/CCM/B501).
Of the 31 completed acute care RCTs, 27 (87%) were pub-
lished as peer-reviewed journal articles or abstracts, and the 
primary outcome was statistically significant in 13 of 27 (41%) 
publications. Of the 28 discontinued acute care RCTs, 15 (54%) 
were published as peer-reviewed journal articles or abstracts, and 
all reported that the primary outcome was not statistically signifi-
cant. Of the five RCTs with unclear completion status, one was 
published with a nonsignificant result for the primary outcome.
Of the 15 acute care RCTs discontinued due to slow recruit-
ment, 7 were subsequently published (in peer-reviewed jour-
nals) and 3 reported causes for slow recruitment. In the first 
trial, unforeseeable changes in the regulatory environment 
TAbLE 2. Completion Status and Reasons of Discontinuation of Acute and Nonacute Care 
Randomized Clinical Trials
Completion Status and  
Reasons For Discontinuation
Critical Care 
(n = 29)
Emergency Care 
(n = 35)
Total Acute Care 
(n = 64)
Total Nonacute Care  
(n = 830)
Completion status (%)
  Completed 12 (41) 19 (54) 31 (48) 544 (66)
  Discontinued 14 (48) 14 (40) 28 (44) 221 (27)
  Unclear 3 (10) 2 (6) 5 (8) 66 (8)
Reason for discontinuation (%)
  Slow recruitment 6 (21) 7 (20) 13 (20) 87 (11)
  Futility 3 (10) 4 (11) 7 (11) 30 (4)
  Benefit/harm 2 (7) 0 2 (3) 31 (4)
  Othera 2 (7) 3 (9) 5 (8) 49 (6)
  Unknown reason 1 (3) 0 1 (2) 24 (3)
a Included other reasons such as administrative, strategic, or financial.
TAbLE 3. Risk Factors for Discontinuation Due to Slow Recruitment
Protocol Characteristics
Discontinued  
Due to Slow  
Recruitment  
(n = 90)a
Completed  
(n = 526)a
Univariable Effect Multivariable Effect
OR (95% CI) p
Adjusted OR  
(95% CI) p
Acute care RCT (vs nonacute 
care) (%)
12 (13) 27 (5) 2.97 (1.44–6.14) 0.003 4.00 (1.72–9.31) 0.002
Investigator sponsorship  
(vs industry) (%)
59 (66) 158 (30) 4.43 (2.76–7.12) < 0.001 4.45 (2.59–7.65) < 0.001
Smaller sample size, median 
(interquartile range)
180 (80–320) 364 (155–800) 1.06 (1.01–1.11)b 0.010 1.05 (1.01–1.09)b < 0.001
Multicenter status (vs single 
center) (%)
71 (79) 470 (89) 0.46 (0.26–0.84) 0.011 1.80 (0.85–3.82) 0.12
No methodologic/logistic support 
reported (vs reported) (%)
62 (69) 279 (53) 1.94 (1.2–3.14) 0.007 1.49 (0.86–2.56) 0.088
Active control (vs placebo/no 
active control) (%)
37 (41) 204 (39) 1.14 (0.72–1.79) 0.58 1.37 (0.83–2.24) 0.22
Crossover design (vs parallel) (%) 8 (9) 21 (4) 2.61 (1.11–6.17) 0.028 2.18 (0.82–5.79) 0.13
No method to predict recruitment 
reported (vs reported) (%)
78 (87) 486 (92) 0.53 (0.27–1.06) 0.073 1.15 (0.52–2.54) 0.74
Pediatric RCT (vs adult) (%) 13 (14) 44 (8) 1.95 (1.00–3.81) 0.049 1.22 (0.57–2.63) 0.61
OR = odds ratio, RCT = randomized clinical trial.
a We limited the analysis to RCTs discontinued for slow recruitment and completed RCTs and excluded 51 pilot RCTs and 8 RCTs that randomized clusters (see 
Methods section for a rationale). We excluded 71 RCTs with missing discontinuation information, 25 RCTs with missing reasons for discontinuation, and 12 
RCTs with missing sample size information.
b In decrements of 100.
Copyright © 2015 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Clinical Investigation
Critical Care Medicine www.ccmjournal.org 7
precluded the participation of several countries. In the sec-
ond trial, the doubt among recruiting physicians regarding 
clinical equipoise of the treatment arms and their discomfort 
in approaching substitute decision makers caused the slow 
recruitment. In the third trial, slow recruitment was a result 
of the complex study protocol—specifically, logistic chal-
lenges related to patient transfer and lack of eligible patients 
due to overly strict inclusion criteria—and poor motivation of 
recruiting physicians who perceived a conflict of interest.
DISCUSSION
In a sample of 894 RCT protocols approved by one of the 
six IRBs from Switzerland, Germany, and Canada, 64 stud-
ies (7%) enrolled patients in an acute care setting. Investiga-
tors of almost half (28 of 64, 44%) of the acute care RCTs 
indicated early discontinuation, and the most commonly 
reported reason for discontinuation (20%) was slow recruit-
ment. The risk for discontinuation due to slow recruitment 
was approximately four-fold higher in acute than in non-
acute care RCTs.
This increased risk may result from recruitment challenges 
that are specific to the acute care setting (e.g., narrow time win-
dows or unavailability of substitute decision makers), a higher 
frequency of general recruitment challenges that are not spe-
cific to the acute care setting (e.g., untested eligibility criteria, 
lack of equipoise for the research, or overly complex study 
protocol) (16), or a combination of both setting-specific and 
nonspecific challenges. However, publications rarely reported 
causes for slow recruitment, and we were therefore unable 
to determine the relative impact of specific and nonspecific 
causes on the increased risk of trial discontinuation due to 
slow recruitment in acute care RCTs.
Only a minority of RCT protocols specified strategies to mit-
igate recruitment challenges such as support by a clinical trial 
unit and measures to sustain recruitment. Furthermore, only 
14% of acute and 9% of nonacute care RCT protocols specified 
a method to predict patient recruitment over time. Of those, 
very few based their prediction on data from a pilot study that 
included an informed consent process. The remainder pre-
dicted recruitment using retrospective or prospective screening 
for eligible patients, which are unreliable methods (16, 17). Rare 
specification of recruitment strategies (since these are often 
documented in internal trial documents such as operation 
manuals and likely underreported in trial protocols) and use of 
unreliable methods to predict recruitment may explain why our 
regression model did not identify a protective effect of explicit 
recruitment prediction on the prevention of slow recruitment.
Apart from the acute care setting, significant risk factors for 
trial discontinuation due to slow recruitment were small sam-
ple size and nonindustry sponsorship, which were factors we 
identified in a previous analysis (12). Larger RCTs may be bet-
ter organized (e.g., conduct by established research networks 
engaging multiple centers and collaboration among experi-
enced investigators), and industry-funded RCTs may be better 
resourced to address the problem of slow recruitment versus 
investigator-initiated trials.
Investigators of acute care RCTs more frequently reported 
a DSMB and more frequently specified interim analyses in the 
protocol than investigators of nonacute care trials. This could 
suggest that trialists in the acute care setting were more sen-
sitized to monitor early evidence of benefit, harm, or futility 
in vulnerable populations or simply reflect the tradition of 
DSMB oversight in trials of acute care interventions.
Strengths of our study include collaboration with six IRBs 
from three countries to document the history of 894 planned 
RCTs. We had full access to the files of all RCTs approved during 
a 3-year period, which provides additional safeguards against 
selection bias. We systematically searched all documents and 
contacted the authors to capture any relevant information 
about the course of the RCT. We involved trained methodolo-
gists to identify eligible studies and abstract data, following 
pretesting and calibration exercises (11). To minimize chance 
associations, we considered only a limited number of variables 
in our statistical model and conducted sensitivity analyses 
using multiple imputations for missing data.
Our study is limited by the reporting quality of the original 
RCT protocols and reports, which did not always transpar-
ently indicate factors that can predispose to trial discontinu-
ation due to slow recruitment (e.g., the extent of preparatory 
or pilot work, logistic barriers, financial, or nonfinancial 
incentives). We used single data extraction for almost 70% 
of protocols, thereby potentially increasing extraction errors. 
However, we used prepiloted extraction forms with detailed 
written instructions, conducted formal calibration exercises 
with all data extractors, and checked extractions from a ran-
dom sample of protocols at several points during the process. 
Agreement was good with no more than two discrepancies in 
answers to 30 main questions of the extraction form. All out-
come data on discontinuation and publication of RCTs were 
verified by a second investigator. Our comparison of acute 
care versus nonacute care RCTs is based on protocols that were 
approved by IRBs more than 10 years ago. Results might differ 
if more recent trials were analyzed. However, discontinuation 
due to recruitment challenges for RCTs in acute care is likely to 
remain. Collaborating with six IRBs in three countries increases 
the generalizability of our results, but findings may differ 
among RCTs performed in other jurisdictions where unique 
trial completion challenges exist, such as developing countries. 
Furthermore, although we reported risk factors for nonpub-
lication in our analysis of the full RCT cohort (12), namely 
early trial discontinuation, industry sponsorship, single-center 
trial, and small sample size, we did not test whether risk fac-
tors differ between acute and nonacute care RCTs; appropriate 
tests for interaction would have low power to either identify or 
exclude such differences. However, we do not expect risk fac-
tors for nonpublication to differ substantially between acute 
and nonacute care RCTs.
Our work provides the basis to test interventions aimed at 
limiting early discontinuation of acute care trials. We believe 
that interventions should primarily focus on the prevention 
of slow recruitment because it was the most frequent reason 
for discontinuation. Multicenter pilot randomized trials that 
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apply the full recruitment protocol could be part of the solu-
tion—they represent an opportunity to identify important 
barriers for recruitment such as lack of eligible patients, dif-
ficulties obtaining informed consent, doubt among recruit-
ing physicians regarding clinical equipoise of the treatment 
arms, or prohibitively complex protocols. A necessary feature 
of such pilot trials would be to include the same screening 
and informed consent processes as in the main trial. Further 
research is necessary to estimate the optimal size and dura-
tion of such pilot trials and the number and type of centers in 
which the pilot trial should be conducted to obtain the most 
stable recruitment estimates. Another possible solution would 
be to develop reliable prediction models for recruitment per-
formance (18). In addition, ongoing attention to recruitment 
trends, and introduction of strategies to sustain, bolster, or 
accelerate recruitment when necessary (19), is also imperative 
for acute care trialists once RCTs are underway.
CONCLUSIONS
Acute care RCTs are more vulnerable to premature discon-
tinuation than nonacute care RCTs and have an approxi-
mately four-fold higher risk of discontinuation specifically 
due to slow recruitment. These results highlight the need 
to develop strategies to reliably prevent and resolve slow 
patient recruitment in RCTs conducted in the critical and 
emergency care setting.
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